
    
      Before enrolling participants, each country was assigned to either cohort 1 (patients
      receiving only darbepoetin alfa) or cohort 2 (patients receiving any ESA). Cohort 2 was
      assigned only to those countries in which local regulations did not permit observational
      study participation by patients receiving a specific agent in a drug class.
    
  